Authors
Margarita L Martinez-Fierro, Samantha Gonzalez-Delgado, Israel A Solis-Hernandez, Maria Del R Rocha-Pizaña, Ana J Mendez-Gonzalez, Idalia Garza-Veloz
Published in
Molecules (Basel, Switzerland). Volume 31. Issue 20. Oct 19, 2026. Epub Oct 19, 2026.
Abstract
Post-COVID-19 condition can include persistent cognitive symptoms, commonly described as impaired attention, memory difficulties, slowed processing, and "brain fog." Clinical and translational evidence implicates systemic inflammation, neurovascular dysfunction, blood-brain barrier disruption, glial inflammatory responses, oxidative stress, and altered synaptic or network function; their relative contributions remain uncertain and may differ across patient subgroups. Resveratrol is a polyphenolic compound that modifies inflammatory, redox, metabolic, endothelial, and antiviral pathways in experimental systems. This focused narrative review examines whether those actions provide a mechanistic basis for the use of resveratrol in post-COVID-19 cognitive dysfunction. Evidence was considered according to biological proximity to the intended indication, distinguishing human post-acute sequelae of SARS-CoV-2 infection (PASC) studies from acute-COVID-19, non-COVID-19 clinical, animal, organoid, and cell-based evidence. The review identifies candidate neurovascular, immune, and metabolic processes, evaluates where resveratrol evidence intersects with those processes, and distinguishes molecular observations from clinical questions that remain to be tested for to define the therapeutic potential of using resveratrol to treat post-COVID-19 cognitive impairment.
PMID:
42943816
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0